ArticleClinical and experimental medicine2026
Unveiling the prognostic and therapeutic landscape of the zinc transporter protein SLC39A family in colorectal cancer through multi-omics and machine learning approaches.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Colorectal cancer (CRC) remains a significant global health challenge due to its high prevalence and mortality rates. Zinc transporter proteins of the SLC39A family are crucial mediators of metal ion transport and have been implicated in numerous diseases, including cancer. However, the specific molecular mechanisms underpinning their impact on CRC progression remain poorly understood. By analyzing thousands of CRC patient samples from large-scale public databases, we constructed a SLC39A family-related signature (SFRS) for prognostic prediction through the integration of 101 combinations of 10 machine learning algorithms. This model was utilized to explore tumor biology, immune microenvironment composition, mutation patterns, and responses to immunotherapy in CRC patients. To reinforce these findings, immunohistochemistry (IHC) analyses were conducted on our in-house cohort (RJ-TMA-Cohort) to examine expression levels of two key molecules, SLC39A8 and SLC39A14, and their associations with CRC progression. The SFRS model demonstrated excellent predictive performance, effectively stratifying CRC patients based on tumor characteristics, immune microenvironment, mutation features, and immunotherapy responses. Moreover, IHC and bioinformatic analyses revealed that SLC39A8 and SLC39A14 expression levels are closely associated with CRC progression, emphasizing their potential roles in tumor microenvironment regulation and their value as biomarkers and therapeutic targets. This study is the first to comprehensively investigate the functions of the SLC39A family in CRC, offering novel insights into their roles in tumor development, prognosis, and potential relevance to immunotherapy response. The SFRS model represents a powerful tool for clinical applications, while SLC39A8 and SLC39A14 present promising avenues for future research and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.